Literature DB >> 18786555

Topiramate attenuates the stress-induced increase in alcohol consumption and preference in male C57BL/6J mice.

Justin M Farook1, Ben Lewis, John M Littleton, Susan Barron.   

Abstract

Stress increases the risk for alcohol abuse and relapse behaviors. However, there are hardly any medications to counteract stress-induced alcoholism and relapse behaviors. The present study examined the effects of topiramate (intraperitoneal injections of 10, 20, and 30 mg/kg) in its ability to attenuate alcohol consumption on exposure to restraint stress in C57BL/6J mice on a 2-choice test procedure. Mice were either restrained for 1h/day for 5 successive days or left unrestrained. Subsequently, the effects of topiramate were studied in post-restraint days. Results showed that restrained animals increased alcohol consumption and alcohol preference significantly compared to control group on day 5. On post-restraint days, topiramate reduced alcohol consumption and alcohol preference on days 2-5 compared to saline. This experiment suggests that one mechanism of topiramate in reducing alcohol consumption and alcohol preference may involve an interaction with stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786555     DOI: 10.1016/j.physbeh.2008.08.011

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  12 in total

Review 1.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

2.  Impact of Genetic Variation on Stress-Related Ethanol Consumption.

Authors:  Megan K Mulligan; Lu Lu; Sonia A Cavigelli; Pierre Mormède; Elena Terenina; Wenyuan Zhao; Robert W Williams; Byron C Jones
Journal:  Alcohol Clin Exp Res       Date:  2019-05-21       Impact factor: 3.455

3.  Environmental stressors influence limited-access ethanol consumption by C57BL/6J mice in a sex-dependent manner.

Authors:  Debra K Cozzoli; Michelle A Tanchuck-Nipper; Moriah N Kaufman; Chloe B Horowitz; Deborah A Finn
Journal:  Alcohol       Date:  2014-10-18       Impact factor: 2.405

Review 4.  Laboratory models available to study alcohol-induced organ damage and immune variations: choosing the appropriate model.

Authors:  Nympha B D'Souza El-Guindy; Elizabeth J Kovacs; Philippe De Witte; Claudia Spies; John M Littleton; Willem J S de Villiers; Amanda J Lott; Timothy P Plackett; Nadine Lanzke; Gary G Meadows
Journal:  Alcohol Clin Exp Res       Date:  2010-06-25       Impact factor: 3.455

Review 5.  Emerging pharmacotherapies for alcohol use disorder.

Authors:  Barbara J Mason
Journal:  Neuropharmacology       Date:  2017-04-25       Impact factor: 5.250

6.  Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models.

Authors:  A E Padula; N S McGuier; W C Griffin; M F Lopez; H C Becker; P J Mulholland
Journal:  OA Alcohol       Date:  2013-02-01

7.  Effect of repeated treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol high-preferring rats.

Authors:  Jadwiga Zalewska-Kaszubska; Bartosz Bajer; Dorota Gorska; Dariusz Andrzejczak; Wanda Dyr; Przemysław Bieńkowski
Journal:  Psychopharmacology (Berl)       Date:  2012-07-31       Impact factor: 4.530

Review 8.  Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

Authors:  George F Koob; G Kenneth Lloyd; Barbara J Mason
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

9.  Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice.

Authors:  Justin M Farook; Ben Lewis; Justin G Gaddis; John M Littleton; Susan Barron
Journal:  Pharmacology       Date:  2009-05-20       Impact factor: 2.547

10.  The antidepressant-like effects of topiramate alone or combined with 17β-estradiol in ovariectomized Wistar rats submitted to the forced swimming test.

Authors:  Miguel Molina-Hernández; N Patricia Téllez-Alcántara; Jorge I Olivera-López; M Teresa Jaramillo
Journal:  Psychopharmacology (Berl)       Date:  2013-08-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.